Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AXGN vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AXGN Captures Overall Composite Edge (33.1 SELL vs 35.9 SELL), While DCTH Leads 4–2 on Growth & Valuation Pillars
AXGN Overall Winner
6-Pillar Tally: AXGN 2 – 4 DCTH
Matrix Metrics: AXGN 5 – 5 DCTH
As of Nov 16, 2026, Axogen, Inc. (AXGN) captures the overall head-to-head institutional edge over Delcath Systems Inc (DCTH) on higher Unified Composite conviction (33.1/100 SELL vs. 35.9/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while DCTH wins 4–2 across the 6-pillar growth and valuation breakdown. AXGN trades at $55.35 (79.3x Forward P/E, -5.2% operating margin) versus DCTH at $19.68 (N/M Forward P/E, 5.2% operating margin).
- Composite vs. Pillar Nuance: While DCTH currently prints a higher short-term Unified Composite Score (35.9/100 SELL vs. AXGN 33.1/100 SELL), AXGN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 5.2% operating margin) and revenue trajectory (+26.2% vs. +70.7% YoY).
- Defensive Composite Rating Caution: Although AXGN compares more favorably head-to-head, both AXGN (33.1/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AXGN vs DCTH
AXGN
Head-to-Head Winner
Axogen, Inc. Common Stock
$55.35
-1.03% 1D
Market Cap
$3.3B
TTM Revenue
$267M
Forward P/E
79.3x
Beta / 30D Vol
1.28β · 123% Vol
Unified Composite Score
33.1
SELL
Tech 50.0
Fund 34.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
DCTH
Delcath Systems Inc
$19.68
-4.23% 1D
Market Cap
$743.8M
TTM Revenue
$110M
Forward P/E
N/M
Beta / 30D Vol
1.63β · 131% Vol
Unified Composite Score
35.9
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (AXGN 2 – 4 DCTH)
1. Valuation Multiples
AXGN
Forward P/E
79.3x
N/M
Trailing P/E
128.2x
133.6x
PEG Ratio
N/M
1.60x
EV / Revenue
11.2x
6.3x
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+26.2%
+70.7%
Earnings Growth (YoY)
+300.0%
+750.0%
TTM Revenue (USD)
$267M
$110M
Market Cap
$3.3B
$743.8M
3. Profitability & Quality
DCTH
Gross Margin
74.2%
87.6%
Operating Margin
-5.2%
5.2%
Net Profit Margin
-12.0%
6.0%
Return on Equity (ROE)
-10.3%
5.4%
4. Balance Sheet & Cash Flow
DCTH
Cash Generation (TTM)
$20M
$20M
Cash Flow Margin
7.5%
18.3%
Net Cash / Leverage
$309M Net Cash
$53M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AXGN
Options Structure Phase
BREAKOUT
BREAKOUT
Current IV / %ile
58.6% (12th %ile)
109.3% (43rd %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
0.11x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Neutral
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
79.4% of Rev ($212M)
82.4% of Rev ($91M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AXGN (5) vs DCTH (5)| Institutional Metric | AXGN | DCTH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $3.3B | $743.8M | AXGN | |
| Trailing P/E Ratio | 128.2x | 133.6x | AXGN | |
| Forward P/E Ratio | 79.3x | N/M | AXGN | |
| Revenue Growth (YoY) | +26.2% | +70.7% | DCTH | |
| Operating Margin (TTM) | -5.2% | 5.2% | DCTH | |
| Net Profit Margin | -12.0% | 6.0% | DCTH | |
| Return on Equity (ROE) | -10.3% | 5.4% | DCTH | |
| 52-Week Range Position | 88% ($23–$60) | 80% ($8–$23) | AXGN | |
| Beta / 30D Volatility | 1.28β · 123% Vol | 1.63β · 131% Vol | AXGN | |
| Unified Institutional Score | 33.1 / 100 (SELL) | 35.9 / 100 (SELL) | DCTH | |
| Trailing 12M Revenue (USD) | $267M | $110M | Scale | |
| Gross Profit Margin (TTM) | 74.2% | 87.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 11.2x EV/Rev | 1.60x PEG · 6.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $20M ($309M Net Cash) | $20M ($53M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AXGN +20.12 pp
3M Horizon
DCTH +6.44 pp
6M Horizon
DCTH +45.51 pp
1Y Horizon
AXGN +1.69 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AXGN Revenue | DCTH Revenue | AXGN Op. Margin | DCTH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $80M | N/A | -24.4% | N/A | AXGN |
| FY2019 | $110M | N/A | -29.4% | N/A | AXGN |
| FY2020 | $110M | N/A | -20.6% | N/A | AXGN |
| FY2021 | $130M | $0M | -20.0% | -690.0% | AXGN |
| FY2022 | $140M | $0M | -21.4% | -1245.1% | AXGN |
| FY2023 | $160M | $0M | -13.5% | -1849.0% | AXGN |
| FY2024 | $190M | $40M | -1.8% | -33.4% | AXGN |
| FY2025 | $230M | $90M | -3.5% | 0.8% | DCTH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AXGN
BREAKOUT
Current IV
58.6%
IV Percentile
12th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact AXGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DCTH
BREAKOUT
Current IV
109.3%
IV Percentile
43rd %ile
Put/Call OI Skew
0.11x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AXGN Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
79.4% of Rev ($212M)
90D Engineering Disclosures
0 Published
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
Investor FAQ AXGN vs DCTH Key Questions & Quantitative Answers
As of Nov 16, 2026, Axogen, Inc. (AXGN) captures the overall head-to-head institutional edge over Delcath Systems Inc (DCTH) on higher Unified Composite conviction (33.1/100 SELL vs. 35.9/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while DCTH wins 4–2 across the 6-pillar growth and valuation breakdown. AXGN trades at $55.35 (79.3x Forward P/E, -5.2% operating margin) versus DCTH at $19.68 (N/M Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While DCTH currently prints a higher short-term Unified Composite Score (35.9/100 SELL vs. AXGN 33.1/100 SELL), AXGN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 5.2% operating margin) and revenue trajectory (+26.2% vs. +70.7% YoY). Defensive Composite Rating Caution: Although AXGN compares more favorably head-to-head, both AXGN (33.1/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
DCTH leads the Growth & Scale pillar: AXGN posts +26.2% YoY revenue growth and +300.0% YoY earnings growth on $267M TTM revenue (74.2% gross margin, -5.2% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AXGN cumulative revenue shifted +187.5% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, AXGN deploys 79.4% of Rev ($212M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
AXGN screens cheaper on headline valuation multiples. AXGN trades at 79.3x Forward P/E, 128.2x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (7.5% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXGN (-10.3% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, AXGN carries 58.6% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.28β · 123% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DCTH vs AXGN · Reverse Pair
AXGN vs ATRC
· Sector Peer
AXGN vs ANAB
· Sector Peer
AXGN vs LIVN
· Sector Peer
DCTH vs CRMD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma